Late immune tolerance induction in haemophilia A patients

Haemophilia

Volumn 19, Issue 3, 2013, Pages 445-448

  Meeks, S L ^a   Chapman, R L ^a   Kempton, C ^a,b   Dunn, A L ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Factor VIII; Haemophilia A; Immune tolerance; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FAMILY HISTORY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; NEGRO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MALE; YOUNG ADULT;

EID: 84876795816     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12077     Document Type: Article

References (26)

1. Bray G. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
2. Kreuz W, Ettingshausen CE, Zyschka A et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002; 28: 285-90.
3. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9. 1993.
4. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. ReFacto Phase 3 Study G. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.[see comment]. Haemophilia 2003; 9: 38-49.
5. Astermark J, Berntorp E, White GC, Kroner BL, Group MS. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
6. Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E. Malmo International Brother Study study g. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. [see comment]. Haematologica. 2005; 90: 924-31. 2005.
7. Goodeve A. The incidence of inhibitor development according to specific mutations-and treatment?. [Review] [8 refs]. Blood Coagul Fibrinolysis 2003; 14(Suppl. 1): S17-21.
8. Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. [Review] [44 refs]. Semin Hematol 2004 Jan; 41(1 Suppl. 1): 82-8. 2004.
9. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
10. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
11. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'bonn protocol'. Vox Sang 1996; 70: 30-5.
12. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. [Review] [55 refs]. Haemophilia 2002; 8: 280-7.
13. DiMichele D. Immune tolerance therapy dose as an outcome predictor. [Review] [25 refs]. Haemophilia 2003; 9: 382-6.
14. DiMichele DM, Kroner BL. North American Immune Tolerance Study G. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
15. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
16. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. American Journal of Pediatric Hematology/Oncology. 1992; 14: 82-7.
17. Lenk H, Group ITTS. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000; 85(10 Suppl.): 45-7.
18. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briet E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost 1994; 71: 703-6.
19. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001; 7: 33-8.
20. Smith MP, Spence KJ, Waters EL et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35-8.
21. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77: 33-7.
22. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
23. Mariani G, Scheibel E, Nogao T et al. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 2: 62-4.
24. Mariani G, Kroner B. International Immune Tolerance Registry, 1997 Update. Vox Sang 1999; 77(Suppl. 1): 25-7.
25. Hay CR, Dimichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
26. Robbins JB, Schneerson R, Keith JM, Shiloach J, Miller M, Trollors B. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP. Vaccine 2007; 25: 2811-6.